Market Entry Strategy for an International Medical Devices Manufacturer Entering Saudi Arabia's Healthcare Sector

A leading international medical devices manufacturer specialising in diagnostic imaging and surgical equipment, seeking to establish a direct commercial presence in Saudi Arabia to capture demand created by Vision 2030's Health Sector Transformation Program. Having served the market historically through third-party distributors, the manufacturer engaged Eurogroup Consulting to design a market entry strategy that would convert its distributor-led position into a sustainable, directly managed commercial operation.

• Distributor Dependency & Limited Market Control: The manufacturer's reliance on third-party distributors limited its visibility of end-customer demand, pricing, and clinical relationships, and constrained its ability to capture the full value of a rapidly expanding market. It required clarity on whether and how to transition to a direct presence.
• Regulatory & Registration Pathway: Medical devices in Saudi Arabia are subject to registration and conformity requirements administered by the Saudi Food and Drug Authority. The manufacturer needed a clear understanding of the registration pathway, timelines, and the operating model implications of regulatory compliance.
• Market Sizing & Segment Prioritisation: The manufacturer lacked an independent, granular view of demand across public hospitals, private healthcare groups, and emerging specialist providers, and could not confidently prioritise the segments, product lines, and geographies offering the strongest near-term return.
• Procurement & Channel Dynamics: Saudi healthcare procurement spanned centralised government purchasing, group purchasing organisations, and private-sector tenders, each with distinct dynamics. The manufacturer needed to understand how to position for each channel and what commercial model each demanded.
• Localisation & Saudization Requirements: Establishing a direct presence triggered foreign investment licensing, localisation expectations, and Saudization obligations. The manufacturer required an entry model that satisfied these requirements while remaining commercially efficient.
  

Eurogroup Consulting was engaged to develop a comprehensive Market Entry Strategy — providing the manufacturer with independent market sizing, segment prioritisation, an evaluated entry-model recommendation, a regulatory and localisation roadmap, and a commercial launch plan to establish a sustainable direct presence in Saudi Arabia's healthcare market.

• Market Sizing & Demand Analysis: Quantified addressable demand across diagnostic imaging and surgical equipment by care setting, segment, and geography, incorporating the hospital construction pipeline, insurance expansion, and Health Sector Transformation Program privatisation initiatives to identify the most attractive near-term opportunities.
• Competitive & Channel Assessment: Mapped the competitive landscape, distributor ecosystem, and procurement channels, assessing pricing benchmarks, clinical decision-maker dynamics, and the relative attractiveness of centralised, group, and private-sector purchasing routes.
• Entry Model Evaluation: Evaluated entry options ranging from an enhanced distributor model and hybrid arrangements to a fully owned commercial subsidiary, assessing each against market control, capital requirements, regulatory feasibility, Saudization obligations, and projected returns.
• Regulatory & Localisation Roadmap: Defined the device registration pathway, foreign investment licensing requirements, and localisation and Saudization obligations, translating them into a sequenced establishment roadmap with realistic timelines and resourcing requirements.
• Commercial Launch Planning: Developed the organisational design, sales and clinical-support model, pricing approach, and phased launch plan required to stand up a direct commercial operation and capture priority segments within the first 24 months.

• Phased Transition to Direct Presence: Recommended a phased transition, retaining selected distributor relationships for lower-priority segments while establishing a wholly owned subsidiary to serve high-value private healthcare groups and major hospital accounts directly, balancing market control against capital and execution risk.
• Priority Segment Focus: Recommended concentrating initial direct effort on private multi-specialty hospital groups and the new-build hospital pipeline, where procurement cycles were faster, clinical relationships more durable, and margins stronger than in centralised public procurement.
• Clinical Partnership Model: Recommended investing in a local clinical applications and training capability as a differentiator, recognising that after-sales clinical support was a decisive purchasing factor in imaging and surgical equipment and a barrier competitors struggled to match.
• Localisation Positioning: Recommended pursuing a localisation roadmap including local assembly or configuration of selected product lines over the medium term, aligning with government preference for localised suppliers and strengthening positioning in public-sector tenders.

• Validated Investment Decision: The independent market sizing confirmed an addressable opportunity sufficient to justify direct entry, giving the manufacturer's board the evidence base to approve the establishment investment with confidence.
• Accelerated Market Access: The regulatory roadmap reduced the manufacturer's expected device registration and licensing timeline by an estimated five months by sequencing applications correctly and pre-empting documentation gaps.
• Revenue Capture: The phased entry model positioned the manufacturer to capture margin previously ceded to distributors, with the direct operation projected to improve gross contribution on priority accounts by approximately 22% relative to the distributor model.
• Segment Win Rate: Focusing initial effort on private hospital groups and the new-build pipeline enabled the manufacturer to secure several anchor accounts within the first year, establishing reference installations that strengthened subsequent tender positioning.
• Compliant, Scalable Platform: The entry established a regulatory- and Saudization-compliant commercial platform designed to scale across additional product lines, providing a durable foundation for long-term growth in the Saudi market.